Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

Table 5 Mean changes from baseline for ER visits and hospitalizations post omalizumab therapy

Duration >120 days	Baseline^a	Follow-up^b	Change from baseline	p-value^c
N = 158	Mean ± SD	Mean ± SD	Mean ± SD
ER visit
(person × times/year)	1.13 ± 2.04	0.29 ± 0.83	−0.83 ± 2.05	<0.001*
Inpatient visit
(person × times/year)	5.93 ± 16.16	2.75 ± 12.02	−3.18 ± 13.03	<0.001*

^aBaseline: 1 year before index day
^bFollow-up: 2 months before discontinuation (discontinuation of therapy was defined as a gap in therapy of 56 days)
^cMean change from baseline by paired T test, *p < 0.05

ISSN: 1471-2466